Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.
Célian BertinJessica DelormeMarie RiquelmeHélène PeyrièreGeorges BrousseAlain EschalierDenis ArdidChouki ChenafNicolas AuthierPublished in: British journal of clinical pharmacology (2019)
This first French comprehensive nationwide study reveals increasing overdose, death, bacterial infection, abuse and diversion risks when off-label MS is initiated as alternative to OST. These results question the relevance of prescribing MS as a safe opioid maintenance treatment, considering its health risk profile.
Keyphrases
- health risk
- risk assessment
- chronic pain
- mass spectrometry
- end stage renal disease
- heavy metals
- pain management
- multiple sclerosis
- ms ms
- ejection fraction
- human health
- newly diagnosed
- primary care
- chronic kidney disease
- prognostic factors
- drinking water
- peritoneal dialysis
- cross sectional
- emergency department
- climate change
- electronic health record